Merck & Co. Files Q1 2025 10-Q
Ticker: MRK · Form: 10-Q · Filed: 2025-05-02T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Merck's Q1 2025 10-Q is in: check financials for latest performance.
AI Summary
Merck & Co., Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position. Key financial data points such as revenue, net income, and cash flows for the quarter are presented, along with balance sheet information as of March 31, 2025.
Why It Matters
This filing provides investors with the latest financial results and operational updates for Merck & Co., Inc., crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial information.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250502 (date) — Filing date
- 0000310158 (company) — Central Index Key for Merck & Co., Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 2, 2025.
What is Merck & Co., Inc.'s Central Index Key (CIK)?
Merck & Co., Inc.'s Central Index Key is 0000310158.
What is Merck & Co., Inc.'s fiscal year end?
Merck & Co., Inc.'s fiscal year ends on December 31.
What is the primary business of Merck & Co., Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code, Merck & Co., Inc. is in the 'Pharmaceutical Preparations' industry.
From the Filing
0001628280-25-021834.txt : 20250502 0001628280-25-021834.hdr.sgml : 20250502 20250502161022 ACCESSION NUMBER: 0001628280-25-021834 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 25908550 BUSINESS ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20250331.htm 1Q25 FORM 10-Q (3.31.25) mrk-20250331 FALSE 2025 Q1 0000310158 12/31 http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent xbrli:shares iso4217:USD iso4217:USD xbrli:shares mrk:candidate xbrli:pure mrk:interest_rate_swap mrk:case mrk:plaintiff mrk:company mrk:patent mrk:segment 0000310158 2025-01-01 2025-03-31 0000310158 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000310158 mrk:A1.875Notesdue2026Member 2025-01-01 2025-03-31 0000310158 mrk:A3.250NotesDue2032Member 2025-01-01 2025-03-31 0000310158 mrk:A2.500Notesdue2034Member 2025-01-01 2025-03-31 0000310158 mrk:A1.375Notesdue2036Member 2025-01-01 2025-03-31 0000310158 mrk:A3.500NotesDue2037Member 2025-01-01 2025-03-31 0000310158 mrk:A3.700NotesDue2044Member 2025-01-01 2025-03-31 0000310158 mrk:A3.750NotesDue2054Member 2025-01-01 2025-03-31 0000310158 2025-04-30 0000310158 2024-01-01 2024-03-31 0000310158 2025-03-31 0000310158 2024-12-31 0000310158 2023-12-31 0000310158 2024-03-31 0000310158 srt:ScenarioForecastMember mrk:HRS5346JiangsuHengruiPharmaceuticalsCo.Ltd.Member 2025-04-01 2025-06-30 0000310158 srt:ScenarioForecastMember mrk:JiangsuHengruiPharmaceuticalsCo.Ltd.Member 2025-06-30 0000310158 mrk:WuXiVaccinesFacilityMember 2025-03-01 2025-03-31 0000310158 mrk:WuXiVaccinesFacilityMember us-gaap:AssetUnderConstructionMember 2025-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-03-01 2024-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-01-01 2024-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2025-01-01 2025-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2025-01-01 2025-03-31 0000310158 mrk:AstraZenecaMember mrk:KoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2025-01-01 2025-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2025-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransa